Overview
STAAR Surgical Q3 preliminary net sales rise 6.9% yr/yr, beating analyst expectations
Sales growth driven by recognition of deferred China shipment
Lower new orders from China due to leaner inventory management
Outlook
STAAR Surgical did not provide specific future guidance in its press release
Result Drivers
DEFERRED CHINA SHIPMENT - Recognition of $25.9 mln from December 2024 shipment boosted Q3 sales
LOWER CHINA ORDERS - Lower new orders from China due to leaner inventory management
INTERNATIONAL GROWTH - 7.7% growth in net sales outside China contributed to overall sales increase
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$94.70 mln
$93.30 mln (7 Analysts)
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for STAAR Surgical Co is $28.00, about 10.6% above its October 17 closing price of $25.03
Press Release: ID:nBw70pTfja
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
